{"": [98, 1850, 0], "Introduction": [1851, 5171, 0], "Novel Coronaviruses": [5208, 6945, 0], "Stages of the Immune Response": [6946, 9078, 0], "Current Immunotherapies": [9079, 14755, 0], "COVID-19 and Current Immunotherapy": [5172, 14755, 1], "Overview": [14770, 15995, 0, 46703, 48914, 0], "Clinical Use of Azithromycin as an Immunomodulator": [15996, 19877, 0], "Antiviral Effects of Azithromycin": [19923, 22619, 0], "Azithromycin Inhibits Inflammatory Cell Signaling": [22620, 26734, 0], "Azithromycin Alters Macrophage Polarization": [26735, 34143, 0], "Azithromycin Directly and Indirectly Impacts Neutrophils": [34144, 35396, 0], "Azithromycin's Impact on Lymphocytes": [35397, 41065, 0], "Azithromycin Inhibits Autophagosome Flux": [41066, 42779, 0], "Immunomodulatory Mechanisms of Azithromycin": [19878, 42779, 1], "Azithromycin": [14756, 42779, 1], "Antiviral Immune Response (Stage 1)": [42847, 46660, 0], "Macrophages": [48915, 55438, 0], "Neutrophils": [55439, 56909, 0], "Lymphocytes": [56910, 60527, 0], "Pathologic Inflammation (Stages 2 and 3)": [46661, 60527, 1], "Immune Pathology of COVID-19 and Potential Impact of Azithromycin": [42780, 60527, 1], "Discussion": [60528, 62272, 0], "Author Contributions": [62273, 62422, 0], "Conflict of Interest": [62423, 62733, 0]}